article thumbnail

Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition

pharmaphorum

Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. In a statement Sanofi said that the acquisition will give it full control of the brain-penetrant BTK inhibitor, SAR442168, making marketing more efficient and eliminating any royalty payments due under the 2017 agreement.

article thumbnail

7 health benefits of raspberry leaf tea

The Checkup by Singlecare

Antioxidants are often associated with a healthy immune system, but they may also stave off disease by protecting cells from damage caused by free radicals. A 2017 study demonstrated that ellagic acid can inhibit pancreatic cancer growth.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

pharmaphorum

Patients will also receive a dose of tacrolimus, an immune-suppressing drug, to guard against any immune reaction to the transplanted cells. The hope is that the spheroids will help to replenish damaged cardiomyocytes in the heart, restoring some of its ability to pump blood around the body. Other readouts give grounds for optimism.

article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells. However, 2017 saw the discontinuation of nabiximols from Phase III development in the US for cancer pain, due to lack of efficacy.

article thumbnail

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin. The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies.

article thumbnail

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Of those who receive a transplant, about 50 percent will ultimately relapse, stated research from 2017, published in the journal Blood. Could CAR T therapies be manufactured in one day?

article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. billion buy of Kite Pharma and followed that earlier this year by acquiring immuno-oncology firm Forty Seven for $4.9